An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided ...

The global Nasal Drug Delivery Technology Market is expected to grow from approximately USD 4.4 billion in 2024 to around USD 7.8 billion by 2031, achieving a compound annual growth rate (CAGR) of ...

Phenylephrine is a medication that’s been used to relieve nasal congestion caused by colds, allergies, and hay fever, per the ...

Milestone Pharmaceuticals (MIST) has released an update. Milestone Pharmaceuticals is gearing up for the potential FDA approval of its CARDAMYST nasal spray for PSVT, with a decision expected by March ...

“Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone ...

Among the latest innovations are tanning nasal sprays and Permatan—two methods that have been generating buzz in the beauty ...

ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal ...

The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...

News reporter for Orlando Weekly, with a focus on state and local government, workers' rights, and housing issues. Previously ...